10 April 2024
10 April 2024
Pfizer intends to submit data from MONeT to regulatory agencies in a bid to expand the vaccine’s indicated treatment population.
BrainStorm Cell Therapeutics has faced a few hurdles along the way towards the development of its lead candidate, NurOwn for ALS.
The Phase I/II trial will assess iadademstat in combination with immune checkpoint inhibitors in lung cancer patients.
The PIKA Rabies Vaccine trial met the primary endpoints, indicating the potential to offer rapid protection.
Treatment-related adverse events in the trial were reported to be Grade 1 or 2 in severity.
SpineX expects market access for its SCONE device later this year.
Prothea plans to use the funds to start clinical trial for cancer imaging, biopsy and laser ablation treatment in lung cancer patients.
Merging industry-leading business intelligence & award-winning journalism, this is an unrivalled opportunity for engagement with B2B professionals across a network of 40+ leading media websites.
Steer your business strategy with key data and insights from our latest market research reports and company profiles. Not ready to buy? Start small by downloading a sample report first.
Give your business an edge with our leading industry insights.
